Treatment
Adjuvant therapy clinical trials
We’re tracking 215 recruiting studies that include Adjuvant therapy, each written for real people, not researchers, below.
Recruiting studies
- NCT07180693Recruiting
Breast cancer that returns after CDK4/6 inhibitor treatment
This study looks at patients whose breast cancer returns after starting a CDK4/6 inhibitor (like abemaciclib or ribociclib) along with hormone therapy. The goal is to understand why the cancer comes back and find better ways to treat it.
Bergamo, ItalyAges 18 years+ - NCT04875585RecruitingPhase 2
Neoadjuvant and post-surgery immunotherapy for operable lung cancer
This trial tests a combination of medicines given before surgery and immunotherapy after surgery for resectable non-small cell lung cancer (NSCLC). It aims to shrink the tumor before the operation and reduce the risk of cancer coming back after surgery.
Innsbruck, TyrolAges 18 years+ - NCT06766578RecruitingPhase 2
Low-dose radiation plus immunotherapy and chemo before gastric cancer surgery
This trial tests a new combination of low-dose radiation, an immunotherapy drug (tirelizumab), and chemotherapy (SOX) given before surgery for locally advanced gastric or gastroesophageal junction cancer. The goal is to see if this approach can shrink tumors more effectively.
Jinan, ShandongAges 18–75 - NCT05909332RecruitingPhase 3
Tested antivascular drug plus chemo versus chemo alone for TNBC
This Phase 3 trial compares an “anti-blood-vessel” drug added to chemotherapy versus chemotherapy alone for people with stage II–IIIC triple-negative breast cancer that has been completely removed with surgery. The goal is to see if adding the study drug improves outcomes after surgery (adjuvant treatment).
Beijing, Beijing MunicipalityAges 18–70 - NCT07837739Recruiting
EGFR-targeted pill after surgery for early lung cancer
This trial tests whether taking an EGFR-targeted pill after lung cancer surgery can lower the chance of the cancer coming back. It is for people with early-stage non-small cell lung cancer that has a specific EGFR mutation.
Wuhan, HubeiAges 18–75 - NCT06271421Recruiting
Nanoparticle heat therapy for recurrent glioblastoma
This trial tests a new treatment for recurrent glioblastoma using tiny magnetic particles (nanoparticles) that are heated to kill cancer cells. The particles are injected into the tumor, and then a magnetic field device heats them up. It's for people who have already tried standard therapy and whose tumor has come back.
PoznanAges 18 years+ - NCT07788196RecruitingPhase 2
Adding anti-HER2 therapy after surgery for early-stage gastric cancer
This trial tests whether adding a targeted therapy (anti-HER2) to standard chemotherapy after surgery can improve outcomes for people with early-stage gastric cancer that has high HER2 levels. It aims to see if the combination is more effective than chemotherapy alone.
Xi'an, ShaanxiAges 18 years+ - NCT07479667RecruitingPhase 1
Targeted immune cell therapy for solid tumors after surgery and chemo
This trial tests a new type of immune cell therapy (dendritic cells) that is designed to target specific proteins found on cancer cells. It is for people with certain solid tumors who have already had surgery and at least 4 cycles of standard chemotherapy after surgery.
ShanghaiAges 18–80 - NCT06617936RecruitingPhase 2
Immunotherapy plus endostatin and chemo for stage III lung cancer
This trial tests a combination of an immunotherapy drug (tislelizumab), an anti-angiogenic drug (endostatin), and standard chemotherapy for people with stage III lung cancer that cannot be surgically removed. The goal is to see if this triple therapy can shrink tumors and improve outcomes.
Jinan, ShandongAges 18–75 - NCT05862064RecruitingPhase 3
Adding an immune drug and anti-blood-vessel treatment to chemo
This study tests whether adding an immune therapy (a PD-1 antibody) plus a blood-vessel–blocking treatment to standard chemo improves outcomes for people with surgically treated triple-negative breast cancer. Everyone gets chemotherapy, but some will also get the added drugs to try to reduce cancer coming back.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05872724RecruitingPhase 2
Personalized add-on treatment after cervical cancer surgery
This study tests whether a tailored “extra” treatment after surgery—guided by a lab test called minimal residual disease (MRD)—can reduce the risk of cervical cancer coming back. It focuses on people with certain stages of cervical cancer who can follow the treatment plan and study follow-up.
Suzhou, JiangsuAges 18 years+ - NCT06693037Recruiting
Choosing next treatment after incomplete response in HER2+ breast cancer
This trial looks at the best next treatment for women with HER2-positive breast cancer who still have leftover cancer after surgery and standard pre-surgery treatment. It helps doctors choose the right therapy for you.
Beijing, Beijing MunicipalityAges Any age - NCT07039656RecruitingPhase 2
Toripalimab plus chemo after NSCLC surgery
This trial tests adding the immunotherapy drug toripalimab to chemotherapy after surgery for non-small cell lung cancer (NSCLC). It is for patients who either had no treatment before surgery or had chemo-immunotherapy before surgery and still have signs of cancer in their lymph nodes. The goal is to see if this combination helps prevent cancer from coming back.
Guangzhou, GuangdongAges 18–75 - NCT05221398Recruiting
Immunotherapy after liver cancer surgery
This trial tests whether giving immunotherapy after surgery to remove liver cancer can help lower the risk of the cancer coming back. It may be an option for people who have certain risk factors for recurrence.
Nanning, GuangxiAges 18–75 - NCT06762782RecruitingPhase 2
Lenvatinib after liver cancer surgery to prevent recurrence
This trial tests whether taking lenvatinib after liver cancer surgery can lower the chance of the cancer coming back. It is for people who have a high risk of recurrence and have recently had their liver tumor completely removed.
Nanjing, JiangsuAges 18–80 - NCT06711068Recruiting
Chemotherapy plus targeted therapy for HER2+ early breast cancer
This trial tests whether adding targeted therapy to chemotherapy after surgery can help prevent HER2-positive early breast cancer from coming back. It is for patients whose cancer has not spread to lymph nodes and who have certain tumor sizes and features.
Beijing, Beijing MunicipalityAges Any age - NCT05179447Recruiting
Study testing added treatment after endometrial cancer surgery
This trial looks at how to guide follow-up (adjuvant) treatment after surgery for certain early-stage, higher-risk endometrial cancer. It may help by tailoring care based on patient and tumor details to lower the chance of the cancer coming back.
Wuhan, HubeiAges 18–75 - NCT05527795Recruiting
Study features that predict benefit from extra immunotherapy in melanoma
This study looks for lab and tumor features that may help predict who benefits from follow-up (adjuvant) immunotherapy after surgery for melanoma. Your past treatment and tumor samples may be used to improve future treatment decisions.
Pierre-BéniteAges 18 years+ - NCT05640999RecruitingPhase 2
Trial for early uterine cancer with POLE mutation after surgery
This Phase 2 trial studies an added (adjuvant) treatment for early-stage uterine cancer that has a specific genetic change called POLE mutation and does not have a p53 abnormal pattern. The goal is to lower the risk of the cancer coming back after surgery.
Anchorage, AlaskaAges 18 years+ - NCT07443774Recruiting
Sticking with hormone and CDK4/6 therapy after breast cancer surgery
This study is looking at how well people stick to a treatment plan that combines hormone therapy with a pill called a CDK4/6 inhibitor after surgery for early-stage breast cancer. The goal is to learn more about adherence so doctors can help patients stay on track.
GrenobleAges 18 years+ - NCT07748325RecruitingPhase 2
Checking if immunotherapy after surgery helps prevent lung cancer return
This trial is for people with non-small cell lung cancer who have already had immunotherapy and chemotherapy before surgery, followed by complete removal of the tumor. It tests whether continuing immunotherapy after surgery (adjuvant treatment) can lower the risk of cancer coming back compared to just watching and waiting.
Chengdu, SichuanAges 18–75 - NCT06939127RecruitingPhase 2
Cold therapy, immunotherapy, and chemo before and after lung cancer surgery
This trial tests a treatment that uses extreme cold (cryoablation) along with immunotherapy (tislelizumab) and chemotherapy before and after surgery for people with early-stage lung cancer that can be removed. The goal is to see if this combination helps prevent the cancer from coming back.
TianjinAges 18–75 - NCT06041776RecruitingPhase 3
Befotertinib after surgery for early-stage lung cancer with EGFR mutation
This trial tests if a targeted therapy pill (befotertinib) can lower the chance of cancer coming back after surgery for non-small cell lung cancer that has a specific EGFR mutation. You may be eligible if your tumor was completely removed and you have stage IB to IIIB disease.
BeijingAges 18 years+ - NCT07581834RecruitingPhase 2
Dalpiciclib plus hormone therapy for early hormone-positive breast cancer
This study tests whether adding a new drug called dalpiciclib to standard hormone therapy improves outcomes for women with early-stage breast cancer that is hormone-receptor positive. The goal is to see if this combination is more effective and safe than hormone therapy alone.
Fuzhou, FujianAges 18 years+
Common questions
- Are there clinical trials studying Adjuvant therapy?
- Yes. Clin2 currently lists 215 recruiting studies that include Adjuvant therapy, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Adjuvant therapy trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Adjuvant therapy an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Adjuvant therapy or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.